References
[1] James H. Strauss, Ellen G. Strauss. (2008). CHAPTER 3—Plus-Strand RNA Viruses, Viruses and Human Disease (Second Edition), Academic Press, 2008, Pages 63-136, ISBN 9780123737410.
[2] Centres of Disease control and prevention via National Center for Immunization and Respiratory Diseases, Division of Viral Diseases.
[3] Habibzadeh P., Stoneman E. K. (2020). The novel coronavirus: A bird’s eye view. International Journal of Occupational and Environmental Medicine, 11(2), pp. 65-71.
[4] https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
[5] Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y. Feng, Z. (2020). Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. New England Journal of Medicine. doi: 10.1056/nejmoa2001316.
[6] Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Cao, B. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. doi: 10.1016/s0140-6736(20)30183-5.
[7] Weiss SR, Navas-Martin S. (2005). Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev. 2005; 69(4): 635‐664. doi:10.1128/MMBR.69.4.635-664.2005.
[8] Lin, L., Lu, L., Cao, W., & Li, T. (2020). Hypothesis for potential pathogenesis of SARS-CoV-2 infection: a review of immune changes in patients with viral pneumonia. Emerging Microbes & Infections, 1-14. doi:10.1080/22221751.2020.1746199.
[9] Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., & Feng, Z. (2020). Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. New England Journal of Medicine. doi: 10.1056/nejmoa2001316.
[10] Centres of Disease control and prevention via National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases.
[11] Rajeev Gupta, Rajinder K Dhamija, Kiran Gaur. (2020). Epidemiological Transition of Covid-19 in India from Higher to Lower HDI States and Territories: Implications for Prevention and Control. medRxiv preprint doi: https://doi.org/10.1101/2020.05.05.20092593.
[12] Palash Ghosh, et al. (2020). COVID-19 in India: State-wise Analysis and Prediction. medRxiv 2020.04.24.20077792; doi: https://doi.org/10.1101/2020.04.24.20077792.
[13] Shi Y., Wang X., Liu G., et al. (2020). A quickly, effectively screening process of novel corona virus disease 2019 (COVID-19) in children in Shanghai, China. Ann Transl Med. 2020; 8(5): 241. doi:10.21037/atm.2020.03.22.
[14] Guan, et al. (2020). Clinical characteristics of 2019 novel coronavirus infection in China. doi: 10.1101/2020.02.06.20020974.
[15] Ding, X., Xu, J., Zhou, J., & Long, Q. (2020). Chest CT findings of COVID-19 pneumonia by duration of symptoms. European Journal of Radiology, 109009. doi:10.1016/j.ejrad.2020.109009.
[16] Cascella M, Rajnik M, Cuomo A, et al. (2020). Features, Evaluation and Treatment Coronavirus (COVID-19) [Updated 2020 Apr 6]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554776/.
[17] Dong, L., Hu, S., & Gao, J. (2020). Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discoveries & Therapeutics, 14(1), 58-60. doi:10.5582/ddt.2020.01012.
[18] Li Q, Guan X, Wu P, et al. (2020). Early transmission dynamics in Wuhan, China, of novel coronavirus‐infected pneumonia. N Engl J Med. 10.1056/NEJMoa2001316. [published online ahead of print January 29, 2020.
[19] Xia J, Tong J, Liu M, Shen Y, Guo D. (2020). Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS‐CoV‐2 infection. J Med Virol. 10.1002/jmv.25725.
[20] Thomas Peter, Baldwin Claire, et al. (2020). Physiotherapy management for COVID-19 in the acute hospital setting: clinical practice recommendations. Journal of Physiotherapy, 66 (2020), pp. 73-82.
[21] Fadel R, Morrison AR, Vahia A, et al. (2020). Early Short Course Corticosteroids in Hospitalized Patients with COVID-19. Clin Infect Dis. 2020; ciaa601. doi:10.1093/cid/ciaa601.